92 related articles for article (PubMed ID: 10356686)
1. Clinical trials referral resource. Clinical trials with gadolinium-texaphyrin and lutetium-texaphyrin.
Ivy SP; Blatner G; Cheson BD
Oncology (Williston Park); 1999 May; 13(5):671, 674-6. PubMed ID: 10356686
[No Abstract] [Full Text] [Related]
2. Phototherapy of cancer and atheromatous plaque with texaphyrins.
Woodburn KW; Fan Q; Kessel D; Wright M; Mody TD; Hemmi G; Magda D; Sessler JL; Dow WC; Miller RA; Young SW
J Clin Laser Med Surg; 1996 Oct; 14(5):343-8. PubMed ID: 9612202
[TBL] [Abstract][Full Text] [Related]
3. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Francis D; Richards GM; Forouzannia A; Mehta MP; Khuntia D
Expert Opin Pharmacother; 2009 Sep; 10(13):2171-80. PubMed ID: 19640206
[TBL] [Abstract][Full Text] [Related]
4. Motexafin gadolinium in the treatment of brain metastases.
Richards GM; Mehta MP
Expert Opin Pharmacother; 2007 Feb; 8(3):351-9. PubMed ID: 17266469
[TBL] [Abstract][Full Text] [Related]
5. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Khuntia D; Mehta M
Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.
Chou TM; Woodburn KW; Cheong WF; Lacy SA; Sudhir K; Adelman DC; Wahr D
Catheter Cardiovasc Interv; 2002 Nov; 57(3):387-94. PubMed ID: 12410519
[TBL] [Abstract][Full Text] [Related]
7. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy.
Sessler JL; Miller RA
Biochem Pharmacol; 2000 Apr; 59(7):733-9. PubMed ID: 10718331
[TBL] [Abstract][Full Text] [Related]
8. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer.
Evens AM
Curr Opin Oncol; 2004 Nov; 16(6):576-80. PubMed ID: 15627019
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy for choroidal neovascular disease: photosensitizers and clinical trials.
Lim JI
Ophthalmol Clin North Am; 2002 Dec; 15(4):473-8, vii. PubMed ID: 12515080
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive and nondestructive optical spectroscopic measurement of motexafin gadolinium in mouse tissues: comparison to high-performance liquid chromatography.
Kanick SC; Eiseman JL; Joseph E; Guo J; Parker RS
J Photochem Photobiol B; 2007 Sep; 88(2-3):90-104. PubMed ID: 17604637
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
[TBL] [Abstract][Full Text] [Related]
12. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.
Miller RA; Woodburn K; Fan Q; Renschler MF; Sessler JL; Koutcher JA
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):981-9. PubMed ID: 10571206
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials referral resource. Multicenter phase I and II trials in adults with high-grade gliomas.
Kaplan RS; Smiley JK; Cheson BD
Oncology (Williston Park); 1999 Apr; 13(4):532-3, 537. PubMed ID: 10234703
[No Abstract] [Full Text] [Related]
14. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.
Rosenthal DI; Nurenberg P; Becerra CR; Frenkel EP; Carbone DP; Lum BL; Miller R; Engel J; Young S; Miles D; Renschler MF
Clin Cancer Res; 1999 Apr; 5(4):739-45. PubMed ID: 10213207
[TBL] [Abstract][Full Text] [Related]
15. Brain tumors.
Obbens EA; Shapiro WR
Cancer Chemother Biol Response Modif; 1993; 14():606-27. PubMed ID: 8312122
[No Abstract] [Full Text] [Related]
16. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
[TBL] [Abstract][Full Text] [Related]
17. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Forouzannia A; Richards GM; Khuntia D; Mehta MP
Expert Rev Anticancer Ther; 2007 Jun; 7(6):785-94. PubMed ID: 17555388
[TBL] [Abstract][Full Text] [Related]
18. Photosensitization of red blood cell hemolysis by lutetium texaphyrin.
Bilgin MD; al Akhras MA; Khalili M; Hemmati H; Grossweiner LI
Photochem Photobiol; 2000 Jul; 72(1):121-7. PubMed ID: 10911736
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy in the canine prostate using motexafin lutetium.
Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
[TBL] [Abstract][Full Text] [Related]
20. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.
Dimofte A; Zhu TC; Hahn SM; Lustig RA
Lasers Surg Med; 2002; 31(5):305-12. PubMed ID: 12430147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
